鉴定植物雌激素作为抗乳腺癌的Sirtuin抑制剂:多目标方法
Venkateswarlu Kojja1, Vanitha Rudraram2, Bhanukiran Kancharla1
1Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi 221005, India.
Computational biology and chemistry
|August 10, 2024
概括
昆醇是一种植物衍生的植物雌激素,有效地抑制乳腺癌细胞中的Sirtuin蛋白. 这项研究强调了库梅斯特作为一种有前途的新疗法策略,用于打击乳腺癌耐药性.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是全球癌症死亡的主要原因,对当前疗法具有很高的耐药性,需要新的治疗策略.
- 信号蛋白的一类,Sirtuins,涉及到细胞过程,并代表乳腺癌的潜在治疗点.
- 植物雌激素,植物衍生化合物具有类似雌激素的特性,已经证明了抗癌活性.
研究的目的:
- 调查各种植物雌激素作为乳腺癌治疗的Sirtuin抑制剂的潜力.
- 为了评估一种特定的植物性雌激素库梅斯特对乳腺癌细胞系的疗效.
- 阐明昆醇在抑制乳腺癌进展中的作用机制.
主要方法:
- 进行了in-silico分子对接和分子动力学研究,以评估植物雌激素与Sirtuin蛋白质1-3-3的结合亲和力.
- 实验室研究包括细胞增殖试验,殖民地形成试验,反应性氧物种 (ROS) 分析的流动细胞计和SIRT-1表达的西部斑分析.
- 乳腺癌细胞系 (MCF-7和MDAMB-231) 用于体外实验.
主要成果:
- 分子对接确定了coumestrol具有与sirtuin蛋白质1-3-3的高结合能量.
- 分子动力学证实了 Estrol 和 Sirtuin 结合位点之间的稳定和高亲和相互作用.
- 库梅斯特显著降低了乳腺癌细胞的增殖和殖民地形成,诱导了细胞内ROS,并降低了SIRT-1表达.
结论:
- 在体和体外试验数据强烈表明,库梅斯特醇表现出Sirtuin抑制活性.
- 库梅斯特对乳腺癌细胞系表现出显著的抗癌作用.
- 植物性雌激素库梅斯特罗尔代表着针对Sirtuins的乳腺癌治疗的有前途的新型治疗候选者.
相关概念视频
02:59Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K